

CardioCel continues to get surgeons' nod in Australia

08 October 2013 | News | By BioSpectrum Bureau



Singapore: CardioCel, a cardiovascular tissue patch to repair heart deformities including repairing and reconstructing heart valves developed by Australia based Allied Healthcare Group, is approved by another eight surgeons at The Prince Charles Hospital in Brisbane.

There are now 14 surgeons in Australia that are authorized to use CardioCel for the repair of heart defects with over 60 patients having successfully received the tissue implant since the initial procedure was performed.

"This is an important approval for Allied as it represents the first department wide team of cardiac heart surgeons to gain early access to use CardioCel for treating and repairing heart defects in adult patients. The adult market has the potential to significantly expand the market and revenue for the Company considerably," stated Mr Lee Rodne, CEO, Allied Healthcare Group.

CardioCel recently received its CE mark in Europe for use in both children and adults. "We are extremely encouraged by the growing support for CardioCel from Australian and International surgeons and these early access approvals further validates the importance of CardioCel in the future treatment of heart defects" said Allied Healthcare Group CEO, Mr Lee Rodne.

The adult market is significant and in the UK alone there are over 30,000 cardiac surgery procedures per annum. Allied Healthcare Group has filed for marketing approval for CardioCel in the US FDA.